Effects of phenobarbital, valproic acid and carbamazepine on serum lipids and lipoproteins in a pediatric population;EFECTOS DEL FENOBARBITAL, ACIDO VALPROICO Y CARBAMAZEPINA SOBRE LIPIDOS Y LIPOPROTEINAS SERICAS EN POBLACION INFANTO-JUVENIL

Anales Espanoles de Pediatria

Volumn 44, Issue 2, 1996, Pages 133-138

  De Juan Frigola, J ^a,b   Crespo Hernandez M ^a   Braga Hernandez S ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b Centro Materno Infantil   (Spain)

Author keywords

anticonvulsant drugs; carbamazepine; lipids; lipoproteins; phenobarbital; valproic acid

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; CARBAMAZEPINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHENOBARBITAL; VALPROIC ACID; ANTICONVULSIVE AGENT;

ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFECT; EPILEPSY; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ADOLESCENT; BLOOD; COMPARATIVE STUDY; INFANT; PRESCHOOL CHILD; TIME;

ADOLESCENT; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; INFANT; LIPIDS; LIPOPROTEINS; MALE; PHENOBARBITAL; TIME FACTORS; VALPROIC ACID;

EID: 0030076129     PISSN: 03024342     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Crespo M, Orense M, Fernández Toral J, De Juan J, Valdés-Hevia J. Osteodistrofia por anticonvulsivantes. Aportación de un caso. An Esp Pediatr 1975;8:533-540.
2. Castro Gago M, Novo I, Bugallo Rivas A, Rodríguez Núñez A, Belmente A. La funcion tiroidea en niños en tratamiento con fármacos anticonvulsivantes. Rev Esp Pediatr 1989;45:26-29.
3. Williams L, Reynolds R, Emery J. Pancreatitis during sodium valproate treatment. Arch Dis Child 1983;58:543-544.
4. Scheffner D, Konig ST, Rauterberg-Ruland I, Konen W, Hoffmann WJ, Unkelbach ST. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988;29:530-542.
5. Horowitz S, Patwardkan R, Marcus E: Hepatotoxic reactions associated with carbamazepine therapy. Epilepsia 1988;29:149-154.
6. Herranz JL, Arteaga R. Efectos secundarios de los fármacos antiepilépticos sobre las funciones cognitivas. Rev Esp Epilepsia 1987;2:174-185.
7. Pellock JM, Cullert JP, Garnett WR, Crumrine PK, Kaplan AM, O'Hara KA, Driscoll SM, Frost MM, Alvin R, Hamer RM, Hauden B, Horowitz IW, Nichols C, Richmond VA, Pittsburg PA, Phoenix AZ. Significant differences of cognitive and behavioral effects of antiepileptic drugs in children. Ann Neurol 1988;24:325-326.
8. Pelkonen R, Fogelholm R, Nikkila E. Increase in serum cholesterol during phenytoin treatment. Br Med J 1975;4:85.
9. Nikkila EA, Kaste M, Ehnholm C, Viikari J. Elevation of High-Density Lipoprotein in epileptic patients treated with phenytoin. Acta Med Scand 1978;204:517-520.
10. Luona PV, Reunanen MI, Sotaniemi EA. Changes in serum triglyceride and cholesterol levels during long-term phenytoin treatment for epilepsy. Aca Med Scand 1979;206:229-231.
11. Heldenberg D, Harel S, Holtzman M, Levtow O, Tamir I. The effect of chronic anticonvulsivant therapy on serum lipids and lipoproteins in epileptic children. Neurology 1983;33:510-512.
12. Muuronen A, Kaste M, Nikkila EA, Tolppanen E. Mortality from ischaemia heart disease among patients using anticonvulsive drugs: A case-control study. Br Med J 1985;291:1481-1483.
13. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA 1971;216:1185-1187.
14. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults Arteriosclerosis Suppl 1 1989;9:19-32.
15. Strong WB, Deckelbaun J, Gidding SS, Kavey RE, Washington R, Wilmore JH, Perry ChL. Integrated cardiovascular health promotion in childhood. A statement for health profesionals from the subcommittee on atherosclerosis and hypertension in childhood of the Council on Cardiovascular Disease in the Young. American Heart Association. AHA Scientific Council. Circulation 1992;85:1638-1650.
16. Goldstein JL, Brown MS. Familial hypercholesterolemia: a genetic receptor disease. Hospital Practice 1985;20:35-46.
17. Humphries SE. DNA polymorphisms of the apolipoproteins genes: their use in the investigation of the genetic component of hyperlipidemia and atherosclerosis. Atherosclerosis 1988;72:89-108.
18. Breslow JL. Genetic basis of lipoprotein disorders. J Clin Invest 1989;84:373-380.
19. Mabuchi H, Koizumi J, Shizmizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989;70:225-232.
20. Muñoz Calvo MT, Argente Oliver J. Colesterol y aterosclerosis en la infancia. An Esp Pediatr 1990;33:203-212.
21. Tojo R, Leis R, Queiro T, Pavón P, Pérez A, Rodríguez Segade S, Gil de la Peña M. Niveles de colesterol en niños y adolescentes: factores de riesto de hipercolesterolemia, «tracking» y agregación familiar. Perfil cardiosaludable. Acta Pediatr Esp 1993;51:28-44.
22. Grande Covián F. Dieta y aterosclerosis en la infancia. Drugs of Today 1988;S-1:197-203.
23. Nicklas TA, Farris RD, Smoak CG, Frank GC, Srinivasan SR, Webber LS, Berenson GS. Dietary factors relate to cardiovascular risk factos in early life. Bogalusa Heart Study. Atherosclerosis 1988;8:193-199.
24. Sarría A, Moreno L, Bueno M Importancia de los ácidos grasos n-3 en alimentación infantil. An Esp Pediatr 1991;35:77-84.
25. American Academy of Pediatrics. Informe sobre el colesterol. Committee on Nutrition. Pediatrics (ed esp) 1992;34:162-167.
26. Ballabriga A. Importancia de la composición de los alimentos en relación al problema hipercolesterolemia-aterogénesis. Acta Pediatr Esp 1993;51:45-53.
27. Kannel WB. Cardiovascular risk factors and «preventive management». Hospital Practice 1987;22:147-164.
28. Grundy SM, Greenland P, Herd A, Huebsch JA, Jones RJ, Mitchell JH, Schlant RC Cardiovascular and risk factor evaluation of healthy american adults. Circulation 1987;75:13440A-1362A.
29. Newman III WP, Freedman DS, Woors AW, Gard PD, Srinivasan SR, Cresanta JL, Williamson GD, Webber LS, Berenson GS. Relation of serum lipoproteins levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med 1986;314.138-144.
30. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?. JAMA 1986;256:2823-2828.
31. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from Framinghan Study. JAMA 1987;257:2176-2180.
32. Davis CE, Rifkind BM, Brenner H, Gordon DJ. A single cholesterol measurement under estimates the risk of coronary heart disease. JAMA 1990;264:3044-3046
33. Steinberg D, Witztum JL. Lipoprotein and atherogenesis. Current concepts. JAMA 1990;264:3047-3052.
34. Castelli WP, Garrison RJ, Willson PWF, Abbott RD, Kalousdian S, Kaunel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framinghan Study JAMA 1986;256:2835-2838.
35. Goldbourt V, Holtzman E, Neufeld HN. Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. Br Med J 1985;290:1239-1243.
36. Superko HR, Bachorik PS, Wood PD. High-Density lipoprotein cholesterol measurements. A help or hindrance in practical clinical medicine?. JAMA 1986;256:2714-2717.
37. Assmann G, Schulte H. The prospective cardiovascular Münster study, prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. Am J Cardiol 1987;59:9G-17G
38. Stampfer ML Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. N Engl J Med 1991;325:373-381.
39. NIH Consensus Conference. Triglyceride, high-density lipoproteins and coronary heart disease. JAMA 1993;269:505-510.
40. Lipid Research Clinics Program: The lipids research clinics coronary primary. Prevention trial results I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
41. Lipid Research Clinics Program: The lipids research clinics coronary primary. Prevention trial results II. The relationship of reduction on incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
42. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JA, Loh IK, Stone NJ, Aldrich RF, Bataglini JW, Moriarty DJ, Fisher MR, Friedman L, Friedewald W, Detre KM, Epstein SE. Effects of therapy with cholestyramine on progression of coronary atherosclerosis results of the NHLBI type II coronary intervention study Circulation 1984;69:313-324.
43. Farriaux JP, Ghisolfi J, Navarro J, Putet G, Rey J, Rieu D, Vidailhet M. Controle dietetique de la cholesterolemie et prevention de l'atherome. Arch Fr Pediatr 1987;44:211-217.
44. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kataniemi P, Koskinen P, Manninen V, Maenpää H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarmen J, Romo M Sjoblom T, Nikkila EA. Helsinki Heart Study: primary prevention trial with gemfibrocil in middle-aged men with dyslipemia. Safetty of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
45. Manninen V, Elo MO, Frick HM, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Mäenpää H, Mälkonen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkila EA Lipide alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-651.
46. Brown BG, Lin JT, Schaefer SM, Kaplan CA, Dodge HT, Albert JJ. Niacin or lovastatin, combined with colestipol regress coronary atherosclerosis and prevent clinical events in men with elevated apolipoproteins B. Circulation 1989;80(Suppl II):266.
47. Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Shapiro DR. Effects of simvastatin and cholestyramine in familiar and nonfamiliar hypercholesterolemia. Arch Intern Med 1990;150:341-345.
48. Kane J, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combines drug regimens. JAMA 1990;264:3007-3012.
49. De Juan Frigola J. Lípidos y lipoproteínas séricas en niños normales y con tratamiento anticonvulsivante. Tesis Doctoral. Universidad de Oviedo, 1990.
50. Richmonde W. Preparation and properties of a cholesterol oxidase from Nocardie sp. and its application to he enzymatic assay of total cholesterol in serum. Clin Chem 1973;19:1350-1356.
51. Allain CC, Poon LS, Chan C. Determination of triglycerides by enzymatic method. Clin Chem 1974;20:470-475.
52. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxidase. Clin Chem 1982;28:2077-2080.
53. Burstein M, Scholnic HR, Morfin R. Rapid method for the isolation of lipoprotein from human serum by precipitation with polianions. J Lip Res 1970;23:882-884.
54. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 1977;23:882-884.
55. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
56. Takayama M, Itoh S, Nagaraki T, Tanimizu I. A new enzymatic method for determination of serum cholinecontaining phospholipids Clin Chem 1977;79:93-96.
57. Trinder P. Method of enzymatic analysis. Ann Clin Biol 1969;6:24-29.
58. Mancini G, Carbonara A, Heremans J. Immunochemical quantitation antigens by single radial immunodiffusion. Immunochemistry 1965;2:235-254.
59. Pita Calandre E, Sinues Porta B, García de la Calzada D. The effect of chronic phenytoin treatment on serum lipid profile in adult epileptic patients. Epilepsia 1992;33:154-157.
60. Luoma PV, Reunanen MI, Sotaniemi A. Changes in serum triglyceride and cholesterol levels during long-term phenytoin treatment for epilepsy. Acta Med Scand 1979;206:229-231.
61. O'Neill B, Callaghan N, Stapleton M, Molloy W. Serum elevation of high density lipoprotein (HDL) cholesterol in epileptic patients takins carbamazepine or phenytoin. Acta Neurol Scand 1982;65:104-109.
62. Berlit P, Krause KH, Hueck CC, Schellenberg B. Serum lipids and anticonvulsivants. Acta Neurol Scand 1982;66:328-339.
63. Glueck CJ. Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis. Am Heart J 1985;110:1107-1115.
64. Kaste M, Muuronen A, Nikkila EA, Neuvonen PJ. Increase of low serum concentrations of high-density lipoprotein (HDL) cholesterol in TIA-patients treated with phenytoin. Stroke 1983;14:525-530.
65. Luoma PV, Sotaniemi EA, Pelkonen RO, Pirttiaho HI. Serum low-density lipoprotein and high-density lipoprotein cholesterol and liver size in subjects on drugs inducing hepatic microsomal enzymes. Eur J Clin Pharmacol 1985;28:615-618.
66. Reddy MM. Effect of anticonvulsant drugs on plasma total cholesterol, high-density lipoprotein cholesterol, and apolipoproteins A and B in children with epilepsy. Proc Soc Exp Biol Med 1985;180:359-363.
67. Calandre EP, Rodriguez-López C, Blázquez A, Cano D. Serum lipids lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand 1991;83:1250-1253.